The World Health Organisation has officially acknowledged the role of Glucagon-Like Peptide-1 (GLP-1) medications, commonly known as weight-loss jabs, in addressing the growing problem of obesity worldwide. In its first-ever guideline on the use of GLP-1 therapies, WHO described obesity as a chronic disease requiring lifelong care. Yet the agency cautioned that supply shortages could loom as demand surges worldwide.
'Obesity is a major global health challenge that WHO is committed to addressing by supporting countries and people worldwide to control it, effectively and equitably. Our new guidance recognises that obesity is a chronic disease that can be treated with comprehensive and lifelong care,' WHO Director-General Dr Tedros Adhanom Ghebreyesus said on the organisation's official website.
